This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MLND vs. ABUS, GHRS, TRVI, EOLS, CAPR, PHAT, UPB, STOK, DNTH, and BCYCShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include Arbutus Biopharma (ABUS), GH Research (GHRS), Trevi Therapeutics (TRVI), Evolus (EOLS), Capricor Therapeutics (CAPR), Phathom Pharmaceuticals (PHAT), Upstream Bio (UPB), Stoke Therapeutics (STOK), Dianthus Therapeutics (DNTH), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector. Millendo Therapeutics vs. Its Competitors Arbutus Biopharma GH Research Trevi Therapeutics Evolus Capricor Therapeutics Phathom Pharmaceuticals Upstream Bio Stoke Therapeutics Dianthus Therapeutics Bicycle Therapeutics Arbutus Biopharma (NASDAQ:ABUS) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends. Do insiders and institutionals hold more shares of ABUS or MLND? 43.8% of Arbutus Biopharma shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ABUS or MLND? Arbutus Biopharma currently has a consensus target price of $5.50, indicating a potential upside of 55.81%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Arbutus Biopharma is more favorable than Millendo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Millendo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor ABUS or MLND? Arbutus Biopharma received 436 more outperform votes than Millendo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformArbutus BiopharmaOutperform Votes43670.66% Underperform Votes18129.34% Millendo TherapeuticsN/AN/A Does the media favor ABUS or MLND? In the previous week, Arbutus Biopharma had 2 more articles in the media than Millendo Therapeutics. MarketBeat recorded 2 mentions for Arbutus Biopharma and 0 mentions for Millendo Therapeutics. Arbutus Biopharma's average media sentiment score of 1.82 beat Millendo Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Overall Sentiment Arbutus Biopharma Very Positive Millendo Therapeutics Neutral Is ABUS or MLND more profitable? Millendo Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Arbutus Biopharma's return on equity of -68.18% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-1,137.65% -68.18% -51.55% Millendo Therapeutics N/A -91.03%-72.44% Which has more risk and volatility, ABUS or MLND? Arbutus Biopharma has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Which has better valuation and earnings, ABUS or MLND? Millendo Therapeutics has lower revenue, but higher earnings than Arbutus Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.40M105.59-$72.85M-$0.41-8.61Millendo TherapeuticsN/AN/A-$36.41MN/AN/A SummaryArbutus Biopharma beats Millendo Therapeutics on 12 of the 14 factors compared between the two stocks. Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$125.87M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.15%P/E RatioN/A8.5026.7819.65Price / SalesN/A263.11404.49152.18Price / CashN/A65.8538.2534.64Price / Book3.716.526.964.59Net Income-$36.41M$143.48M$3.23B$248.23M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$6.61-7.0%N/A+130.1%$125.87MN/A0.0012Gap DownABUSArbutus Biopharma2.2184 of 5 stars$3.55+1.1%$5.50+54.9%+11.7%$679.92M$6.40M-8.2690Positive NewsGHRSGH Research1.7693 of 5 stars$12.84-6.3%$32.00+149.2%+0.9%$668.04MN/A-16.2510Analyst RevisionTRVITrevi Therapeutics3.6471 of 5 stars$6.51+1.6%$18.63+186.1%+119.9%$650.30MN/A-14.8020Positive NewsAnalyst RevisionEOLSEvolus4.0557 of 5 stars$9.87+2.3%$23.75+140.6%-14.3%$636.38M$275.46M-10.85170Insider TradeCAPRCapricor Therapeutics2.2523 of 5 stars$13.89+3.8%$35.50+155.6%+122.7%$634.45M$17.36M-13.10N/AAnalyst ForecastOptions VolumeAnalyst RevisionGap DownPHATPhathom Pharmaceuticals3.9524 of 5 stars$8.97+1.6%$17.50+95.1%-2.8%$626.23M$81.86M-1.58110Gap DownHigh Trading VolumeUPBUpstream Bio1.7491 of 5 stars$11.59+2.7%$56.50+387.5%N/A$623.47M$2.30M0.0038Gap DownSTOKStoke Therapeutics3.6046 of 5 stars$11.36+2.1%$23.20+104.2%-34.2%$620.22M$190.91M-5.41100Analyst RevisionGap DownDNTHDianthus Therapeutics1.3745 of 5 stars$18.75+3.1%$53.00+182.7%-32.1%$603M$6.52M-7.5080Analyst RevisionBCYCBicycle Therapeutics3.3459 of 5 stars$8.64+1.2%$25.00+189.4%-65.6%$598.36M$25.72M-2.63240News CoverageAnalyst Revision Related Companies and Tools Related Companies ABUS Alternatives GHRS Alternatives TRVI Alternatives EOLS Alternatives CAPR Alternatives PHAT Alternatives UPB Alternatives STOK Alternatives DNTH Alternatives BCYC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLND) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
